title: Imaging: Mass spectrometry in HNSCC--a peek at response prediction?
abstract: EGFR inhibitors provide benefit in patients with advanced and metastatic head and neck squamous cell carcinoma (HNSCC). Mass spectrometry profiling has been used to predict outcome in patients with HNSCC after EGFR inhibitor treatment, and may enable prior identification of patients most likely to benefit from these therapies. however, further validation in prospective studies is needed.
authors.affiliation: Lineberger Comprehensive Cancer Center, University of North Carolina, 450 West Drive, Chapel Hill, NC 27599-7295, USA.
authors.forename: Mei-Kim
authors.initials: MK
authors.lastname: Ang
authors.forename: D Neil
authors.initials: DN
authors.lastname: Hayes
mesh_terms: D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D013058:Mass Spectrometry; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D066246:ErbB Receptors